Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Becton, Dickinson and Co.

BDX

Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

Last trade $215.79
Day change -$0.68 (-0.31%)
Day range $214.47 – $217.28
Volume 769,140
Market cap $58.96B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$58.96B
Price / earnings
62.66×
Price / book
2.41×
Price / sales
2.83×
EV / sales
3.6×
EV / EBITDA
13.58×

Profitability

Earnings per share
$3.45
Return on assets
1.85%
Return on equity
3.85%
Dividend yield
1.99%

Liquidity and leverage

Debt / equity
0.69×
Current ratio
0.87×
Quick ratio
0.51×
Cash ratio
0.08×

Cash flow

Price / cash flow
18.09×
Price / free cash flow
23.29×
Free cash flow
$2.53B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BDX, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$4.98B$4.71B$5.25B$5.89B$4.73B$4.48B$5.17B$5.44B
Cost of revenue$2.67B$2.56B$2.84B$3.09B$2.49B$2.62B$2.93B$2.95B
Gross profit$2.32B$2.15B$2.41B$2.8B$2.24B$1.86B$2.24B$2.49B
Selling, general and administrative$1.26B$1.21B$1.39B$1.37B$1.16B$1.12B$1.32B$1.26B
Research and development$258M$249M$306M$322M$230M$232M$343M$302M
Total operating expenses$1.65B$2.06B$1.81B$1.82B$1.5B$1.48B$1.75B$1.73B
Operating income$663M$93M$601M$981M$739M$384M$482M$759M
Interest expense-$132M-$149M-$153M-$155M-$152M-$150M-$155M-$155M
Income before taxes$554M$39M$392M$510M$569M$201M$306M$514M
Income taxes$102M$76M$11M$17M$118M$43M$3M$114M
Net income$378M-$311M$381M$493M$574M$308M$303M$400M
Net income attributable to common shareholders$377M-$311M$382M$493M$574M$308M$303M$400M
EBITDA$1.32B$1.15B$1.33B$1.74B$1.41B$1B$1.18B$1.52B
Basic earnings per share$1.37-$1.11$1.34$1.72$2.00$1.07$1.05$1.38
Diluted earnings per share$1.37-$1.11$1.34$1.71$2.00$1.07$1.04$1.36

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

Three healthcare dividend stocks—AbbVie, Gilead Sciences, and Becton, Dickinson—have significantly outperformed the S&P 500 in 2026, with gains of 29%, 37%, and 43% respectively. All three are recommended as continued buys due to strong underlying businesses, solid dividend programs (two are Dividend Kings), and favorable long-term growth prospects driven by key product pipelines and market tailwinds.

Zacks Investment Research

Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?

Boston Scientific (BSX) lowered its 2026 sales growth forecast to 4.25% and adjusted EPS guidance to $3.16-$3.18 due to unexpected headwinds in its WATCHMAN and Electrophysiology franchises. WATCHMAN organic sales fell 5.9% amid weakening demand, while Electrophysiology declined 5.3% due to competitive pressure from Pulsed Field Ablation technologies. The company faces additional challenges from delayed product launches, elevated debt levels, and a cybersecurity incident that accelerated competitive share losses. BSX shares have declined 53.5% year-to-date, significantly underperforming peers and the broader market.

GlobeNewswire Inc.

Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.

Zacks Investment Research

3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility

Following a significant market crash where the Nasdaq dropped 5.5% and $2.3 trillion in market value was wiped out due to tech stock selloffs and AI concerns, three companies recently announced dividend increases: Becton Dickinson ($1.06/share, 8th hike in 5 years), Cencora ($0.66/share, 6th hike in 5 years), and UniFirst ($0.38/share, 6th hike in 5 years). These dividend-paying stocks are highlighted as potential defensive investments for conservative investors seeking steady income during market turbulence.

Zacks Investment Research

BDX Stock Down in Pre-Market Despite Q4 Earnings & Revenue Beat

Becton, Dickinson and Company (BD) delivered better-than-expected Q4 fiscal 2026 results with adjusted EPS up 27.3% and revenues up 5.4%, driven by growth across all four business segments. However, the stock fell 6.4% in pre-market trading due to weak fiscal 2027 guidance projecting only low-single-digit revenue growth and adjusted EPS of $13.10-$13.30. Concerns also include sluggish Connected Care revenue growth and declining Medication Management Solutions sales.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $1.06 per share
Declared
Nov 5, 2026
Ex-dividend
Dec 10, 2026
Pay date
Dec 31, 2026
Ex-dividendAmount / sharePay dateType
Sep 9, 2026$1.05Sep 30, 2026recurring
Jun 9, 2026$1.05Jun 30, 2026recurring
Mar 10, 2026$1.05Mar 31, 2026recurring
Dec 8, 2025$1.05Dec 31, 2025recurring
Sep 8, 2025$1.04Sep 30, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.